Literature DB >> 14500027

Multicenter evaluation of the fully automated Bactec MGIT 960 system for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide: comparison with the radiometric Bactec 460TB system.

Fanourios Kontos1, Stavroula Nicolaou, Christos Kostopoulos, Zoe Gitti, Efthymia Petinaki, Maria Maniati, Spyridoula Anagnostou, Aikaterini Raftopoulou, Panagiota Papageorgiou, Aggeliki Scrioubellou, Ioannis Tselentis, Antonios N Maniatis.   

Abstract

One hundred and fifty clinical isolates of Mycobacterium tuberculosis were tested for susceptibility to pyrazinamide using the fully automated Bactec MGIT 960 system and the radiometric Bactec 460TB system. The overall concordance rate between MGIT 960 and radiometric system was 100% and the mean turnaround times to report the susceptibility test results were almost identical (6.37 and 6.8 days, respectively).

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14500027     DOI： 10.1016/s0167-7012(03)00142-8

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN： 0167-7012            Impact factor:   2.363


  8 in total

Review 1.  Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems.

Authors:  Claudio Piersimoni; Armando Olivieri; Luca Benacchio; Claudio Scarparo
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

2.  Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Pamela Chedore; Lina Bertucci; Joyce Wolfe; Meenu Sharma; Frances Jamieson
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

3.  Author's response to: Acid-fast bacilli culture positivity and drug resistance in abdominal tuberculosis.

Authors:  C Rodrigues; H Samant; D Desai; P Abraham; A Joshi; S George
Journal:  Indian J Gastroenterol       Date:  2015-03

4.  Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.

Authors:  Michael G Whitfield; Robin M Warren; Elizabeth M Streicher; Samantha L Sampson; Frik A Sirgel; Paul D van Helden; Alexandra Mercante; Melisa Willby; Kelsey Hughes; Kris Birkness; Glenn Morlock; Annelies van Rie; James E Posey
Journal:  J Clin Microbiol       Date:  2015-08-19       Impact factor: 5.948

5.  Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Authors:  J Werngren; E Sturegård; P Juréen; K Ängeby; S Hoffner; T Schön
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

6.  Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide.

Authors:  Zhenling Cui; Jie Wang; Junmei Lu; Xiaochen Huang; Ruijuan Zheng; Zhongyi Hu
Journal:  J Clin Microbiol       Date:  2013-02-06       Impact factor: 5.948

7.  Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.

Authors:  Kathleen F Walsh; Ariadne Souroutzidis; Stalz Charles Vilbrun; Miranda Peeples; Guy Joissaint; Sobieskye Delva; Pamphile Widmann; Gertrude Royal; Jake Pry; Heejung Bang; Jean W Pape; Serena P Koenig
Journal:  Am J Trop Med Hyg       Date:  2019-02       Impact factor: 2.345

Review 8.  A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis.

Authors:  Michael G Whitfield; Heidi M Soeters; Robin M Warren; Talita York; Samantha L Sampson; Elizabeth M Streicher; Paul D van Helden; Annelies van Rie
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.